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Studies in animals show that fibroblast growth factor (FGF)-
23 interferes with vascular reactivity induced by the nitric
oxide (NO) system. To investigate the relationship between
circulating FGF-23 levels and the response of forearm blood
flow to ischemia (flow-mediated vasodilatation, FMD) and
nitroglycerin, we tested 183 patients with stage 3–4 chronic
kidney disease (CKD). None of them had cardiovascular
complications or were taking drugs interfering with vascular
function. Patients with FGF-23 levels above the median had
significantly lower glomerular filtration rate, FMD, and fetuin-
A levels (an anti-inflammatory molecule and potent inhibitor
of calcification). They also had higher proteinuria and
phosphate levels when compared to patients whose FGF-23
levels were below the median. The response to nitroglycerin
was not different between the two groups. Multiple
regression analysis showed that the relationship between
FGF-23 and FMD was only modestly sensitive to adjustment
for classical risk factors, biomarkers of bone mineral
metabolism, high-sensitivity C-reactive protein, and
homeostatic model assessment index. Adjustment for
asymmetrical dimethyl arginine (ADMA) weakened the
strength of this link; however, it remained highly significant.
There was no independent association between FGF-23 and
nitroglycerin. Thus, attenuation of FMD by ADMA suggests
that this endogenous inhibitor of NO synthase may, in part,
mediate the vascular effects of FGF-23 in patients with CKD.
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Endothelial dysfunction has now emerged as a relevant risk
factor for major cardiovascular events in the general
population1 and in chronic kidney disease (CKD) patients,
from the predialysis stages of disease2 to end-stage renal
disease.3 At variance with findings in the general population
that identified classical risk factors as the major drivers for
endothelial dysfunction,4 studies in CKD and end-stage renal
disease patients have shown that nontraditional risk factors5
such as accumulation of endogenous inhibitors of nitric
oxide (NO) synthase, high C-reactive protein (CRP), and
some adipose tissue cytokines such as adiponectin and
visfatin6 and hemoglobin7 are the major correlates of this
alteration in patients with CKD. Interestingly, in CKD
patients factors that regulate bone homeostasis such as
fetuin-A and parathyroid hormone (PTH)8 are associated
with reduced hemodynamic response to ischemia in the
forearm, a classical test of endothelial function. In contrast, it
has been recently demonstrated that phosphate intake
physiologically contributes to the regulation of flow-
mediated vasoregulation in healthy, young individuals.9
These observations are cognate to findings in end-stage renal
disease patients showing robust, inverse associations between
the response to this test and circulating 25 hydroxy-vitamin
D (25OHVD) and 1,25 dihydroxy-vitamin D.10 Collectively,
these studies point to endothelium as a target for factors that
regulate bone mineral metabolism.
Fibroblast growth factor 23 (FGF-23) is a primary
regulator of renal phosphate excretion.11 FGF-23 is inversely
associated with the glomerular filtration rate (GFR),12 a
relationship underlying a fundamental mechanism for
maintaining serum phosphate constancy during CKD
progression. Such an adaptation may have deleterious
trade-offs because, independently of serum phosphate,
high FGF-23 signals a high risk of death in end-stage
renal disease patients.13 FGF-23 is expressed both in the
myocardium and in the vascular system.14 An association
between FGF-23 and left ventricular hypertrophy15 has
recently been reported in CKD patients and in elderly people
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in the general population.16 In contrast, a large study
in apparently healthy individuals with GFR 460ml/min
per 1.73m2 in the general population documented a
monotonical, inverse association between FGF-23 and the
forearm blood flow response to ischemia.17 Whether
alterations in circulating FGF-23 are implicated in vascular
dysfunction in CKD is unknown. Given the peculiar risk
factor profile of patients with CKD, the question appears
of relevance for our understanding of the complex relation-
ship between the bone–kidney axis and cardiovascular
disease. With this background in mind, we investigated the
relationship between plasma FGF-23 levels and the forearm
blood flow response to ischemia in the forearm in a sizable
series of incident stage 3–4 CKD patients. To avoid the
confounding effect of classical risk factors and drug
treatments on vascular function, a critical issue in diseased
people,4,18 we excluded from the study patients who were
exposed to major factors that may modify vascular function
and/or FGF-23 levels, namely, smokers and diabetic patients
as well as patients with background cardiovascular events
and those who were on angiotensin-converting enzyme
inhibitors, angiotensin II blockers, statins, and vitamin D
compounds.
RESULTS
The demographic, clinical, and biochemical characteristics of
the study population, as categorized according to the median
FGF-23 value (36.7 pg/dl), are given in Table 1.
Categorical analyses of FGF-23 and other risk factors
Patients in the category with higher FGF-23 levels had a lower
GFR (P¼ 0.008), L-arginine (P¼ 0.006), and L-arginine/
adjustment for asymmetrical dimethyl arginine (ADMA)
ratio (P¼ 0.003), but higher ADMA (P¼ 0.02), proteinuria
(P¼ 0.03), and phosphate levels (P¼ 0.001). On this
categorical analysis, flow-mediated vasodilatation (FMD)
(P¼ 0.01) but not nitroglycerin-mediated vasodilatation
(NMD) (P¼ 0.37) was significantly less in patients with
FGF-23 above than in those below the median value. Fetuin-
A levels (P¼ 0.01) were lower in patients with FGF-23 above
the median. Plasma 25OHVD tended to be lower in patients
with high FGF-23 but the difference was not significant
(P¼ 0.12). There were no differences for age, gender, body
mass index, blood pressures, low-density lipoprotein-choles-
terol, serum calcium and phosphate, PTH, hemoglobin,
symmetrical dimethyl arginine, and high-sensitivity CRP
levels of patients with FGF-23 above the median and those
below the median.
Linear regression analyses of FGF-23 and other risk factors
To better characterize the categorical associations of serum
FGF-23 and to identify the linear correlates of FMD, we first
performed simple regression analyses between these variables
and all variables listed in Table 1.
Data analysis with FGF-23 and FMD as continuous
variables let emerge a close association between these two
parameters (Figure 1). FMD (r¼0.31, Po0.001) while this
Table 1 | Demographic, hemodynamic, and biochemical data in nondiabetic CKD 3–4 patients categorized according to median
FGF-23 value (36.7 pg/ml)
CKD Patients (n=183) o36.7 pg/dl (n=94) X36.7 pg/dl (n=89) P-value
Age (years) 45±13 45±13 44±12 0.57
Male sex, n (%) 92 (49) 53 (43) 51 (55) 0.51
BMI (kg/m2) 24.7±2.7 24.8±2.7 24.6±2.7 0.66
Systolic pressure (mmHg) 133±9 134±9 133±9 0.34
Diastolic pressure (mmHg) 85±4 85±4 84±4 0.26
Calcium (mg/dl) 8.3±0.5 8.3±0.5 8.4±0.5 0.71
Phosphate (mg/dl) 4.9±1.2 4.6±0.9 5.3±1.4 0.001
iPTH (pg/dl) 138.2±26.6 140.1±27.9 136.3±24.9 0.30
25OHVD (nmol/l) 49.5±10.2 51.1±10.8 47.9±9.4 0.12
LDL-cholesterol (mg/dl) 117±17 118±16 117±17 0.88
Insulin (UI/L) 7.2±1.4 7.3±1.5 7.1±1.3 0.79
HOMA index 1.6±0.3 1.5±0.4 1.6±0.3 0.53
hsCRP (mg/l) 18 (6–34) 18 (6–32) 19 (8–34) 0.61
GFR (ml/min per 1.73m2) 33±13 36±13 31±12 0.008
Proteinuria (g/24 h) 1.5±0.9 1.6±0.9 1.3±0.7 0.03
ADMA (mmol/l) 3.5±1.1 3.3±0.9 3.7±1.1 0.02
SDMA (mmol/l) 2.9±0.8 2.8±0.8 2.9±0.8 0.59
L-arginine (mmol/l) 81.3±10.9 83.3±9.4 79.2±11.4 0.006
L-arginine/ADMA 24.9±7.3 26.5±6.9 23.3±7.4 0.003
Fetuin-A (ng/ml) 0.28±0.04 0.29±0.04 0.27±0.04 0.01
Uric acid (g/dl) 4.5±1.1 4.3±1.0 4.6±1.2 0.17
Hb (g/dl) 11.5±1.3 11.5±1.5 11.5±1.1 0.75
NMD (%) 12.7±0.8 12.7±0.8 12.6±0.9 0.37
FMD (%) 6.8±0.9 7.0±0.9 6.6±0.8 0.01
Abbreviations: ADMA, asymmetric dimethyl arginine; BMI, body mass index; CKD, chronic kidney disease; FGF, fibroblast growth factor; FMD, flow-mediated dilatation; GFR,
glomerular filtration rate; Hb, hemoglobulin; HOMA, homeostasis model assessment; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; NMD,
nitroglycerin-mediated vasodilatation; 25OHVD, 25 hydroxy-vitamin D; iPTH, intact parathyroid hormone.
Data are expressed as mean±s.d., median (min–max), or as percent frequency, as appropriate.
Bold values: Po0.05, statistically significant; SDMA, symmetrical dimethyl arginine.
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hormone was only weakly related with NMD (r¼ 0.20,
P¼ 0.006). FGF-23 was also directly related with ADMA
(r¼ 0.28, Po0.001) (Figure 1) and inversely associated with
25OHVD (r¼0.30, Po0.001), GFR (r¼0.25, P¼ 0.001),
L-arginine (r¼0.21, P¼ 0.004), L-arginine/ADMA
(r¼0.33, Po0.001), and fetuin-A (r¼0.28, Po0.001)
levels.
Apart from being inversely associated with FGF-23, FMD
correlated directly with the GFR (r¼ 0.27, Po0.001) and
fetuin-A (r¼ 0.36, Po0.001), and inversely with ADMA
(r¼0.41, Po0.001), symmetrical dimethyl arginine
(r¼0.19, P¼ 0.009), L-arginine/ADMA (r¼ 0.32,
Po0.001), 24 h proteinuria (r¼0.16, P¼ 0.04), systolic
blood pressure (r¼0.38, Po0.001), and high-sensitivity
CRP (r¼0.20, P¼ 0.007).
Multivariate analysis
To analyze the independent contribution of FGF-23 to the
variance of FMD (Table 2), we constructed a series of
multiple regression models based on traditional and
nontraditional risk factors impacting upon this variable. In
the unadjusted analysis, the FGF-23 and FMD levels were
negatively correlated (Figure 1 and Table 2). Adjustment for
the full set of Framingham risk factors did not produce any
change in the correlation coefficient of the association.
Further adjustment for indicators of renal function (GFR,
proteinuria) and hemoglobin produced a moderate decrease
(model 2: b¼030, model 3: b¼023, see Table 2) in the
strength of the FGF-23–FMD correlation, which remained
highly significant (Po0.001). Adjustment for emerging risk
factors (ADMA, high-sensitivity CRP, homeostatic model
assessment index, symmetrical dimethyl arginine, and
L-arginine) substantially reduced the regression coefficient
(model 3: b¼0.15, Table 2), which still remained highly
significant (P¼ 0.009). Further analysis showed that of the
three emerging risk factors added to model 3 variables,
ADMA was the sole variable responsible for the attenuation
of the strength of the FGF-23–FMD association (Figure 2).
This phenomenon suggests that this methylarginine is in the
pathway, whereby high FGF-23 impairs endothelial function.
Further adjustment for risk factors related with bone-mineral
metabolism (calcium, phosphate, PTH, 25OHVD) did not
modify the correlation coefficient of the FGF-23–FMD link
(model 4: b¼0.15) (Table 2). The weak NMD–FGF-23 link
was abolished after statistical adjustment (crude b¼0.20,
P¼ 0.006; adjusted b¼0.09, P¼ 0.24).
DISCUSSION
This survey in patients with CKD shows that, independently
of other traditional and nontraditional risk factors, high
FGF-23 is associated with vascular dysfunction in this
population.
Over the last decade a variety of experimental, clinical, and
intervention studies documented that, in addition to
hypertension and other classical risk factors, endothelial
dysfunction, vascular calcification,19 oxidative stress,20 and
inflammation21 are risk factors of paramount importance in
CKD patients. In previous studies we showed that ADMA, a
NO synthase inhibitor, is implicated in endothelial dysfunc-
tion in CKD.20–22 We also reported that vascular dysfunction
in CKD is associated with low levels of fetuin-A,8 an anti-
inflammatory molecule and a potent inhibitor of the
calcification process. This observation, which involved a
factor considered as a primary in bone homeostasis, went
along with findings indicating that vitamin D metabolites
such as 25OHVD and calcitriol are strongly associated with
FMD in stage 5D CKD patients.10 Altogether, these data
provided a rationale basis for the study of the bone–vascular
connection in CKD and for planning mechanistic and
intervention studies in this population.
FGF-23 has fully emerged as a central factor in the
complex control of mineral metabolism.11 Recent studies
suggest that increased FGF-23 may contribute to the adverse
outcomes in CKD because, independently of serum phos-
phate, it is associated with mortality,13 left ventricular
hypertrophy,15 and progression of CKD.12 FGF-23 is co-
expressed with klotho in the vascular system and experiments
performed in the klotho null mouse, a model characterized by
extensive vascular calcification, strongly suggest that FGF-23 is
an important factor in endothelial cell biology.23 This mouse
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Figure 1 | The association between FGF-23 and endothelial dysfunction. Relationship between fibroblast growth factor (FGF)-23 and
flow-mediated vasodilatation (FMD) (a) and asymmetrical dimethyl arginine (ADMA) (b).
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has no FGF-23 activity because klotho is an obligatory
co-receptor for FGF-23 functioning. The vasoactive response
of aortic rings of klotho null mice to acetylcholine and
noradrenaline is totally abolished.24 Furthermore, elegant
experiments of parabiosis demonstrated that endothelial
function in the klotho null mouse can be fully restored by
connecting the circulatory system of this mouse with that of
the wild-type mouse.25 The vascular response to klotho—
FGF-23 is critically dependent on the NO system because no
immunostaining for NO is found in the aorta of the klotho
null mouse. More recent studies also documented that the
FGF-23 null mouse has a biochemical phenotype almost
identical to that of the klotho null mice and that also this
knockout model undergoes severe vascular calcifications.26
Information on the putative interference of FGF-23 on
vascular function in humans is very limited. At variance with
the klotho null model, a recent population-based study17
showed that high rather than low FGF-23 is associated with
reduced vasoreactivity in individuals with normal renal
function. Even though this apparently paradoxical associa-
tion demands specific mechanistic studies, it is well known
that other major vasoregulatory substances induce similar
effects at very low and very high concentrations in in vitro
models.27 In the population-based study mentioned above,17
the FGF-23–FMD relationship was confined to individuals
with a GFR460ml/min, whereas no such an association was
found in a subgroup of 208 patients with mild-to-moderate
CKD. Furthermore, at variance with in vitro experiments that
identify the endothelium as the critical layer involved in the
response to klotho–FGF-23,28 in this population-based study
FGF-23 was inversely related with both the endothelium-
dependent and independent vascular response implying that
not only the endothelial cells but also the vascular smooth
cells are involved in the response to FGF-23. In this study in a
large series of stage 3 and 4 CKD patients with an average
GFR of 33ml/min, most of which with moderate-to-severe
proteinuria, FGF-23 was coherently associated in an inverse
manner with FMD both on categorical and noncategorical
analyses. On the other hand, FGF-23 was unrelated with
NMD on categorical analyses and only weakly related with
this parameter on crude linear regression analysis, an
association that was abolished by adjustment for other
pertinent risk factors. These findings suggest that the vascular
effects of FGF-23 in CKD patients are mainly mediated by the
Table 2 |Multiple regression models of FMD in CKD 3 and 4 patients
Unadjusted (b, P) Model 1 (b, P) (r2=0.23) Model 2 (b, P) (r2=0.34) Model 3 (b, P) (r2=0.49) Model 4 (b, P) (r2=0.51)
FGF-23 0.30 (o0.001) 0.30 (o0.001) 0.23 (o0.001) 0.15 (0.009) 0.15 (0.007)
Age (years) 0.09 (0.25) 0.08 (0.29) 0.08 (0.29) 0.08 (0.32)
Sex 0.05 (0.54) 0.01 (0.86) 0.01 (0.89) 0.02 (0.83)
BMI 0.08 (0.30) 0.11 (0.16) 0.08 (0.30) 0.06 (0.46)
SBP 0.37 (o0.001) 0.32 (o0.001) 0.34 (o0.001) 0.33 (o0.001)
LDL-cholesterol 0.008 (0.92) 0.02 (0.76) 0.06 (0.46) 0.08 (0.31)
GFR 0.27 (o0.001) 0.23 (o0.001) 0.22 (o0.001)
Proteinuria 0.13 (0.09) 0.09 (0.22) 0.06 (0.44)
Hemoglobin 0.23 (o0.001) 0.28 (o0.001) 0.28 (o0.001)
HOMA 0.18 (0.001) 0.19 (o0.001)
hsCRP 0.10 (0.18) 0.12 (0.11)
ADMA 0.37 (o0.001) 0.38 (o0.001)
SDMA 0.09 (0.23) 0.11 (0.16)
L-arginine 0.14 (0.07) 0.14 (0.07)
Calcium 0.03 (0.74)
Phosphate 0.09 (0.26)
PTH 0.13 (0.02)
25OHVD 0.04 (0.62)
Fetuin-A 0.07 (0.38)
Abbreviations: ADMA, asymmetric dimethyl arginine; BMI, body mass index; CKD, chronic kidney disease; FGF, fibroblast growth factor; FMD, flow-mediated dilatation;
GFR, glomerular filtration rate; HOMA, homeostasis model assessment; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; NMD, nitroglycerin-mediated
vasodilatation; 25OHVD, 25 hydroxy-vitamin D; PTH, parathyroid hormone; SBP, systolic blood pressure; SDMA, symmetrical dimethyl arginine.
Bold values: Po0.05, statistically significant.
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Figure 2 | Influence of adjustment of high-sensitivity
C-reactive protein (hsCRP), homeostatic model assessment
(HOMA) index, and asymmetrical dimethyl arginine (ADMA)
on the correlation coefficient (b) of the fibroblast growth
factor (FGF-23)–flow-mediated vasodilatation (FMD)
relationship. The correlation coefficient was unaffected
by hsCRP and HOMA but was substantially attenuated after
adjustment for ADMA. Nonetheless, also after adjustment
for ADMA, the FGF-23–FMD link remained highly significant
(P¼ 0.009).
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endothelium. Even though directionally similar, the relation-
ships we found in CKD differ from population-based data by
Mirza et al.,17 for three important aspects: first, in Mirza
study FGF-23 was a correlate of vascular function only in
individuals with normal renal function; second, in Mirza
study the FGF-23–vascular function link involved both
endothelium- and nonendothelium-mediated vasoregula-
tion, whereas in our study this connection was largely
confined to the endothelium-dependent component. Third,
individuals studied by Mirza et al. were elderly (70 years)
people with a relevant proportion (20%) of people with
background cardiovascular comorbidities, whereas patients
enrolled in our study were incident middle age and young
patients (average age 45 years) who were specifically selected
because of the absence of cardiovascular complications.
Endothelium-independent (nitroglycerin or nitroprussiate
mediated) vasoregulation is strongly influenced by age.29,30
In the elderly, endothelium-independent vasoreactivity
appears more closely related to cardiovascular risk factors
than the endothelium-dependent responses.29 Furthermore,
although not reported, in Mirza study in the subgroup of 208
individuals with reduced GFR, CKD must have been of
moderate degree, a possibility also suggested by the fact that
vascular reactivity in these individuals was almost identical to
that of individuals with normal renal function. Disturbed
vasoregulation is indeed almost universal in patients with
severely compromised renal function.
An intriguing finding in our study is that FGF-23 was
directly associated with a biomarker of endothelial dysfunc-
tion similar to ADMA, an endogenous inhibitor of NO
synthase. As mentioned, the effects of the klotho–FGF-23
complex in endothelial cell are mediated by the NO system
because they are abolished by the inhibitors of NO
synthase.28 This biological connection is relevant for the
interpretation of our data because we noted that ADMA
attenuated the strength of the FGF-23–FMD link to a
considerable extent, a phenomenon suggesting that FGF-23
and ADMA are in the same pathway that is conducive to
vascular dysfunction, generating a hypothesis that can be
tested in experimental studies. Yet, although much attenuated
after adjustment for ADMA and other potential confounders,
the FGF-23–FMD link remained robust and highly signifi-
cant, an observation which implies that FGF-23 per se has a
direct influence on endothelial function.
This study has limitations. First, the cross-sectional nature
of our observations preclude cause–effect inferences about the
FMD–FGF-23 link we observed. Second, we did not measure
plasma 1,25 dihydroxy-vitamin D, a critical factor for mineral
metabolism intimately connected with FGF-23, which has
also been implicated in the control of vascular tone. However,
this weakness is in part offset by the fact that we adjusted the
analysis for 25OHVD, which is tightly associated with 1,25
dihydroxy-vitamin D levels in CKD patients.31 Third, we did
not perform an intervention to see whether modifications of
FGF-23 levels induce changes in vascular reactivity. In this
regard, it is worth noting that our cross-sectional data are in
keeping with a recent clinical trial showing that a physiolo-
gical oral load of phosphate, the main factor stimulating
FGF-23 release, produces a clearcut decrease in FMD in
young healthy individuals.9
In conclusion, FGF-23 is an independent correlate of
vascular reactivity in CKD and ADMA in patients with CKD.
The attenuation of the link between FGF-23 and FMD by
ADMA suggests that this endogenous inhibitor of NO
synthase may the pathway by which FGF-23 impairs vascular
function in CKD patients.
MATERIALS AND METHODS
Patients
The Ethical Committee of Gulhane School of Medicine
(Etlik-Ankara, Turkey) approved the study, and all patients gave
their informed consent.
Between May 2005 and October 2009, 411 patients with CKD 3–4
were refereed to the Nephrology outpatient clinics of Gulhane
School of Medicine. By protocol, we excluded diabetic patients,
smokers, and patients with established atherosclerotic complication
(coronary artery disease, congestive heart failure, or peripheral
vascular disease). Patients who were being treated with angiotensin-
converting enzyme inhibitors (n¼ 46), angiotensin receptor block-
ers (n¼ 31), statins (n¼ 21), vitamin D (n¼ 18), or taking
polivitamins including folic acid and vitamin B12 (n¼ 14) were
also excluded. Overall, 183 nondiabetic patients, classified as
KDOQI stage 3 (n¼ 90) and stage 4 (n¼ 93), could be enrolled
into this study. None had acute infections at the time of the study.
Protenuria was of mild degree (o1g/24 h) in 54 patients, of
moderate degree (1–3g/24 h) in 118 patients, and of severe degree
(43g/24 h) in 11 patients.
The etiology of renal disease was as follows: glomerulonephritis
(n¼ 42), hypertensive nephropathy (n¼ 40), Chronic pyelonephri-
tis (n¼ 14), reflux nephropathy (n¼ 10), autosomal polycystic
kidney disease (n¼ 18), unknown (n¼ 59). Twenty-one patients
were on calcium channel blockers, 12 on a-blockers, and 7 on
diuretics. Part of the data was published elsewhere.7
Laboratory measurements
All samples were obtained from patients in the morning after 12 h of
fasting, for measurement of fasting plasma glucose, low-density
lipoprotein-cholesterol, calcium and phosphate. Total plasma
cholesterol and high-density lipoprotein-cholesterol were measured
by enzymatic colorimetric method using Olympus AU 600
auto-analyzer with reagents from Olympus Diagnostics, GmbH
(Hamburg, Germany). Low-density lipoprotein-cholesterol was
calculated by Friedewald’s formula.32 Twenty-four hour urine
collection was performed three times and the average of three 24 h
proteinuria measurements was taken as representative of each
participant 24 h protein excretion rate.
Patients were classified with respect to estimated GFR calculated
according to the simplified version of the Modification of Diet, in
Renal Disease formula as defined by Levey et al.33
The serum basal insulin value was determined by the coated
tube method (DPC, Los Angeles, CA, USA). Homeostasis model
assessment-insulin resistance (HOMA-IR) was computed by the
following formula:34 HOMA-IR¼ fasting plasma glucose (mg/dl)
immunoreactive insulin (mIU/ml)/405. Serum total calcium was mea-
sured by the cresolphtalein complex one method usingMenagent Calcium
60sec kits (Menarini Diagnostics, Florence, Italy). Serum phosphorus
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was measured by the ammonia molybdate complex method using
Menagent Phosphofix kits (Menarini Diagnostics). For the mea-
surement of high-sensitivity CRP, serum samples were diluted with a
ratio of 1/101 with the diluents solution. Calibrators, kit controls,
and serum samples were all added on each micro well with an
incubation period of 30min. After three washing intervals, 100 ml
enzyme conjugate (peroxidase-labeled anti-CRP) was added on each
micro well for additional 15min incubation in room temperature in
dark. The reaction was stopped with a stop solution and photometric
measurement was performed at the 450 nm wavelength. The amount
of serum samples was calculated as mg/l with a graphic that was made
by noting the absorbance levels of the calibrators.
Serum FGF-23. Intact FGF-23 was measured using an enzyme-
linked immunosorbent assay according to the manufacturer’s
protocol (Kainos Laboratories International, Tokyo, Japan). This
second-generation, two-site, monoclonal antibody enzyme-linked
immunosorbent assay has previously been shown to recognize the
biologically active, intact FGF-23. The Kainos Intact FGF-23 assay
has a lower limit of detection of 3 pg/ml and intra-assay and inter-
assay coefficients of variation of less than 5%. The calculated overall
intra-assay coefficient of variation was 2.5%, and the calculated
overall inter-assay coefficient of variation was 2.8%. We measured all
samples in duplicate.
ADMA, serum 25OH vitamin D3, PTH, fetuin-A. Measurement
of serum ADMA, symmetrical dimethyl arginine, and L-arginine was
done using high-performance liquid chromatography, as previously
described into detail.20,22 In brief, to 1ml serum, 20mg of
5-sulfosalisilic acid was added and the mixture was left in an ice-
bath for 10min. The precipitated protein was removed by
centrifugation at 2000 g for 10min. Ten micro liters of the
supernatant, which was filtered through a 0.2 mm filter, was mixed
with 100 ml of derivatization reagent (prepared by dissolving 10mg
o-phtaldialdehyde in 0.5ml of methanol, 2ml of 0.4 M borate buffer
(pH 10.0) and 30 ml of 2-mercaptoethanol) and then injected into
the chromatographic system. Separation of ADMA was achieved
with a 150 4mm I.D. Nova-pak C18 column with a particle size of
5 mm (Waters, Millipore, Milford, MA, USA) using 50mM sodium
acetate (pH 6.8), methanol, and tetrahydrofurane as mobile phase
(A, 82:17:1; B, 22:77:1) at a flowrate of 1.0ml/min. The areas of
peaks detected by the fluorescent detector (Ex: 338 nm; Em: 425 nm)
were used as quantification. The variability of the method was less
than 7%, and the detection limit of the assay was 0.01 mM.
To measure 25OHVD, we used high-performance liquid chromato-
graphy kits following manufacturer’s instructions (ImmuChrom GmbH,
Heppenheim, Germany. Quantification of 25-OH vitamin D3 was made
by high-performance liquid chromatography system with UV (264nm)
detector (Thermo Electron, San Jose, CA, USA). The intra-assay
coefficient of variation was 0.9–2.9%, and the calculated inter-assay
coefficient of variation was 1.7–3.9% and recovery was 91%. Intact PTH
was measured by IRMA, using a commercial kit (Immulite Intact PTH)
from Diagnostic Product Corporation (Los Angeles, CA, USA) with a
sensitivity of 1pg/ml. Serum fetuin-A (AHSG) was measured by a
Human fetuin-A ELISA kit (BioVendor Laboratory Medicine, Palackeho
tr. 56, 612 00 Brno, Czech Republic) in an enzyme-linked immuno-
sorbent assay plate reader (Synergy HT, Multidetection Multi Plate
Reader, Bio-Tek Instruments, Highland Park, Winooski, VT, USA).
Vascular assessment
Arterial pressure was measured by a physician three times after a
15-min resting period in the morning, and mean values were
calculated for systolic and diastolic pressures for all patients.
Endothelium-dependent FMD and endothelium-independent vaso-
dilatation (NMD) of the brachial artery was assessed noninvasively,
using high-resolution ultrasound as described by Celermajer et al.35
The method for the vascular assessment met the criteria which were
mentioned by the International Brachial Artery Reactivity Task
Force.36
Measurements were made by a single observer using an ATL 5000
ultrasound system (Advanced Technology Laboratories, Bothell, WA,
USA) with a 12-Mhz prob. All vasoactive medications were withheld for
24h before the procedure. The subjects remained at rest in the supine
position for at least 15min before the examination started. Subject’s arm
was comfortably immobilized in the extended position to allow consistent
recording of the brachial artery 2–4 cm above the antecubital fossa. Three
adjacent measurements of end-diastolic brachial artery diameter were
made from single two-dimensional frames. All ultrasound images were
recorded on S-VHS video cassette recorder (SVO-9500 MDP, Sony,
Tokyo, Japan) for subsequent blinded analysis. A pneumatic tourniquet
was inflated to 300mmHg with obliteration of the radial pulse.
After 5min, the cuff was deflated. Flow measurements were made
60 s post-deflation. After a further 15min measurements were
repeated, and again 3min after administration of sublingual glyceryl
trinitrate (400 mg). The maximum FMD and NMD diameters were
calculated as the average of the three consecutive maximum
diameter measurements after hyperemia and nitroglycerin, respec-
tively. The FMD and NMD were then calculated as the percent
change in diameter compared with baseline resting diameters.
Statistical analysis
All the statistical analyses were performed by SPSS 11.0 (SPSS,
Chicago, IL, USA) statistical package. Non-normally distributed
variables were as median (range) and normally distributed variables
were expressed as mean±s.d. as appropriate. A P-value o0.05 was
considered to be statistically significant. Differences among the
groups were analyzed by Student t test. Standard correlation analysis
was used for testing associations between paired variables. Finally,
multiple regression analysis was applied to test the independent link
between vascular function and potential functional correlates of this
outcome variable. To this scope, we computed models of increasing
complexity adjusting for traditional (Framingham risk factors) and
emerging risk factors. Multivariate models were of adequate
statistical power because included at least 10 observations for each
covariate in the same models.
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